VNRX - VOLITIONRX LTD
2.78
2.644 95.101%
Share volume: 377,519
Last Updated: 04-28-2026
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances:
0.03%
PREVIOUS CLOSE
CHG
CHG%
$0.14
0.06
0.02%
View ratios
| Fiscal Date | 03-31-2024 | 09-30-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-13-2024 | 11-14-2024 | 05-15-2025 | 08-14-2025 | 11-13-2025 | |
| Total revenue | 171.535 K | 474.522 K | 246.385 K | 406.688 K | 627.277 K | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 171.535 K | 474.522 K | 246.385 K | 406.688 K | 627.277 K | |
| 176.63% | -48.08% | 65.06% | 54.24% | |||
| Operating expenses | 8.556 M | 5.290 M | 4.851 M | 5.661 M | 4.770 M | |
| Selling general and admin | 3.927 M | 1.816 M | 2.243 M | 2.941 M | 2.484 M | |
| Research and development | 4.630 M | 3.474 M | 2.607 M | 2.720 M | 2.286 M | |
| Total expenses | 8.556 M | 6.343 M | 5.768 M | 6.704 M | 5.728 M | |
| -25.86% | -9.07% | 16.23% | -14.56% | |||
| Operating income | -8.385 M | -5.869 M | -5.522 M | -6.298 M | -5.101 M | |
| Ebit | -8.385 M | -5.780 M | -5.380 M | -5.866 M | -4.537 M | |
| Pretax income | -8.472 M | -5.869 M | -5.477 M | -6.314 M | -5.410 M | |
| -30.73% | -6.68% | 15.29% | -14.32% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -8.367 M | 0.000 | 0.000 | 0.000 | 0.000 | |
| 100.00% | ||||||
| Net income | -8.367 M | -5.869 M | -5.477 M | -6.314 M | -5.410 M | |
| 29.86% | 6.68% | -15.29% | 14.32% |